Goals Case Study Newly Diagnosed Low Volume Metastatic Disease CHAARTED Benefit of Docetaxel Toxicity Grade 3 AE or Greater Treating the Primary Tumor Case Study Continued Abiraterone COUAA302 Trial ID: 514077
Download Presentation The PPT/PDF document "For the Urologist by the Urologist: Esse..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Slide1
For the Urologist by the Urologist: Essential Concepts in Managing mCRPCSlide2Slide3
GoalsSlide4
Case Study: Newly Diagnosed Low Volume Metastatic DiseaseSlide5
CHAARTED: Benefit of DocetaxelSlide6Slide7
Toxicity Grade 3 AE or GreaterSlide8
Treating the Primary TumorSlide9
Case Study, ContinuedSlide10
Abiraterone COU-AA-302 TrialSlide11
Enzalutamide PREVAIL TrialSlide12
Treatment Considerations: Use of Immunotherapy Slide13
Sipuleucel-TSlide14
Treatment Considerations: Abiraterone vs EnzalutamideSlide15
Case Study: mCRPC Progressing Through Second Generation Androgen Axis InhibitorsSlide16
Further Treatment ConsiderationsSlide17
Emerging BiomarkersSlide18
Biomarkers: Mutations of DNA Repair and High Rate of Response to OlaparibSlide19Slide20
CabazitaxelSlide21
ConclusionsSlide22
Remaining Questions